1. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism
- Author
-
Cecilia M. Shikuma, Star Seyedkazemi, Debra Ogata-Arakaki, Robert H. Paul, Brooks I. Mitchell, Maegen Walker, Lishomwa C. Ndhlovu, Beau K. Nakamoto, Kalpana J. Kallianpur, Laurent Fischer, Lindsay B Kohorn, Eric Lefebvre, and Michelle L DʼAntoni
- Subjects
Male ,0301 basic medicine ,CCR2 ,Receptors, CCR5 ,Anti-HIV Agents ,Receptors, CCR2 ,HIV Infections ,Pilot Projects ,Neuropsychological Tests ,Pharmacology ,Monocytes ,Article ,Leukocyte Count ,03 medical and health sciences ,Chemokine receptor ,Cognition ,parasitic diseases ,Humans ,Medicine ,Pharmacology (medical) ,Receptor ,Cluster of differentiation ,business.industry ,Monocyte ,Antagonist ,Macrophage Activation ,Middle Aged ,Viral Load ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,Female ,business ,Antagonism ,Viral load - Abstract
OBJECTIVE: To evaluate changes in neuropsychological (NP) performance and in plasma and cell surface markers of peripheral monocyte activation/migration following treatment with cenicriviroc (CVC), a dual C-C chemokine receptor type 2 (CCR2) and type 5 (CCR5) antagonist, in treatment-experienced, HIV-infected individuals. SETTING: Single-arm, 24-week, open-label clinical trial. METHODS: HIV-infected individuals on antiretroviral therapy (ART) ≥1 year with plasma HIV RNA ≤50 copies/ml and below-normal cognitive performance [defined as age, gender and education-adjusted NP performance (NPZ)
- Published
- 2018
- Full Text
- View/download PDF